Cilengitide affects tumor compartment, vascularization and microenvironment in experimental bone metastases as shown by longitudinal 18F-FDG PET and gene expression analysis

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 4, 2013, Pages 573-583

  Bretschi, Maren ^a   Cheng, Caixia ^a   Witt, Hendrik ^a,b   Dimitrakopoulou Strauss, Antonia ^a   Strauss, Ludwig G ^a   Semmler, Wolfhard ^a   Bäuerle, Tobias ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

18F FDG PET; Bone metastases; Breast cancer; Cilengitide; Gene expression analysis; Integrins

Indexed keywords

ALPHAVBETA5 INTEGRIN; ANGIOPOIETIN 2; CADHERIN; CELL PROTEIN; CHEMOKINE RECEPTOR CXCR4; CILENGITIDE; CLAUDIN; COLLAGEN; COLLAGEN TYPE 4; EPIDERMAL GROWTH FACTOR; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; HERMES ANTIGEN; HEXOKINASE 1; HEXOKINASE 3; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE RELATED PROTEIN; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; ROUNDABOUT HOMOLOG 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR PROTEIN P53 INDUCIBLE PROTEIN 11; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; BONE MARROW; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MODEL; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; EXPERIMENTAL NEOPLASM; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOME ANALYSIS; HUMAN; HUMAN CELL; LONGITUDINAL STUDY; NEOPLASM; NONHUMAN; OSTEOLYSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; TREATMENT RESPONSE; TUMOR COMPARTMENT; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION PROFILING; HUMANS; INTEGRIN ALPHAVBETA3; LONGITUDINAL STUDIES; MALE; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, NUDE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, VITRONECTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SNAKE VENOMS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84876413609     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1360-6     Document Type: Article

References (33)

1. Alghisi GC, Ponsonnet L, Ruegg C (2009) The integrin antagonist cilengitide activates αvβ3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS ONE 4:e4449
2. Bäuerle T, Adwan H, Kiessling F, Hilbig H, Armbruster FP, Berger MR (2005) Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein. Int J Cancer 115:177-186
3. Bäuerle T, Merz M, Komljenovic D, Zwick S, Semmler W (2010) Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study. Clin Cancer Res 16:3215-3225
4. Bäuerle T, Komljenovic D, Merz M, Berger MR, Goodman SL, Semmler W (2011) Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged non-invasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study. Int J Cancer 128:2453-2462
5. Beekman KW, Colevas AD, Cooney K, Dipaola R, Dunn RL, Gross M, Keller ET, Pienta KJ, Ryan CJ, Smith D, Hussain M (2006) Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin Genitourin Cancer 4:299-302
6. Bretschi M, Merz M, Komljenovic D, Berger MR, Semmler W, Bäuerle T (2011) Cilengitide inhibits metastatic bone colonization in a nude rat model. Oncol Rep 26:843-851
7. Brown JE, Coleman RE (2011) Denosumab in patients with cancer-a surgical strike against the osteoclast. Nat Rev Clin Oncol 9:110-118
8. Brown RS, Goodman TM, Zasadny KR, Greenson JK, Wahl RL (2002) Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol 29:443-453
9. Cheng C, Komljenovic D, Pan L, Dimitrakopoulou-Strauss A, Strauss L, Bäuerle T (2011) Evaluation of treatment response of cilengitide in an experimental model of breast cancer bone metastasis using dynamic PET with 18F-FDG. Hell J Nucl Med 14:15-20
10. Clezardin P (2009) Integrins in bone metastasis formation and potential therapeutic implications. Curr Cancer Drug Targets 9:801-806
11. Clezardin P (2011) Therapeutic targets for bone metastases in breast cancer. Breast Cancer Res 13:207
12. Curtis TM, McKeown-Longo PJ, Vincent PA, Homan SM, Wheatley EM, Saba TM (1995) Fibronectin attenuates increased endothelial monolayer permeability after RGD peptide, anti-α5β1, or TNF-alpha exposure. Am J Physiol 269:L248-L260
13. De S, Razorenova O, McCabe NP, O'Toole T, Qin J, Byzova TV (2005) VEGF-integrin interplay controls tumor growth and vascularization. Proc Natl Acad Sci USA 102:7589-7594
14. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10:9-22
15. Haberkorn U, Hoffend J, Schmidt K, Altmann A, Bonaterra GA, Dimitrakopoulou Strauss A, Strauss LG, Eisenhut M, Kinscherf R (2007) Changes in glucose metabolism and gene expression after transfer of anti-angiogenic genes in rat hepatoma. Eur J Nucl Med Mol Imaging 34:2011-2023
16. Iorns E, Clarke J, Ward T, Dean S, Lippman M (2012) Simultaneous analysis of tumor and stromal gene expression profiles from xenograft models. Breast Cancer Res Treat 131:321-324
17. Li N, Zhang JP, Guo S, Min J, Liu LL, Su HC, Feng YM, Zhang HL (2012) Down-regulation of β3-integrin inhibits bone metastasis of small cell lung cancer. Mol Biol Rep 39:3029-3035
18. Mas-Moruno C, Rechenmacher F, Kessler H (2010) Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem 10:753-768
19. Max R, Gerritsen RR, Nooijen PT, Goodman SL, Sutter A, Keilholz U, Ruiter DJ, De Waal RM (1997) Immunohistochemical analysis of integrin αvβ3 expression on tumor-associated vessels of human carcinomas. Int J Cancer 71:320-324
20. Meyer T, Marshall JF, Hart IR (1998) Expression of αv integrins and vitronectin receptor identity in breast cancer cells. Br J Cancer 77:530-536
21. Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584-593
22. Nemeth JA, Cher ML, Zhou Z, Mullins C, Bhagat S, Trikha M (2003) Inhibition of αvβ3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis 20:413-420
23. Pan L, Mikolajczyk K, Strauss LG (2007) Machine learning based parameter imaging and kinetic modelling of PET data. J Nucl Med 48(suppl 2):158
24. Pecheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Bourre F, Margue C, Cohen-Solal M, Buffet A, Kieffer N, Clezardin P (2002) Integrin αvβ3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 16:1266-1268
25. Pedersen MW, Holm S, Lund EL, Hojgaard L, Kristjansen PE (2001) Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer (SCLC) sublines in vivo and in vitro. Neoplasia 3:80-87
26. Reardon DA, Neyns B, Weller M, Tonn JC, Nabors LB, Stupp R (2011) Cilengitide: an RGD pentapeptide αvβ3 and αvβ5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol 7:339-354
27. Reynolds AR, Hart IR, Watson AR, Welti JC, Silva RG, Robinson SD, Da Violante G, Gourlaouen M, Salih M, Jones MC, Jones DT, Saunders G, Kostourou V, Perron-Sierra F, Norman JC, Tucker GC, Hodivala-Dilke KM (2009) Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 15:392-400
28. Shimamura N, Matchett G, Solaroglu I, Tsubokawa T, Ohkuma H, Zhang J (2006) Inhibition of integrin αvβ3 reduces blood-brain barrier breakdown in focal ischemia in rats. J Neurosci Res 84:1837-1847
29. 18F-FDG in colorectal tumors. J Nucl Med 49:1238-1244
30. Strauss LG, Hoffend J, Koczan D, Pan L, Haberkorn U, Dimitrakopoulou- Strauss A (2009) Early effects of FOLFOX treatment of colorectal tumour in an animal model: assessment of changes in gene expression and FDG kinetics. Eur J Nucl Med Mol Imaging 36:1226-1234
31. van der Horst G, van den Hoogen C, Buijs JT, Cheung H, Bloys H, Pelger RC, Lorenzon G, Heckmann B, Feyen J, Pujuguet P, Blanque R, Clement-Lacroix P, van der Pluijm G (2011) Targeting of αv-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer. Neoplasia 13:516-525
32. Weilbaecher KN, Guise TA, McCauley LK (2011) Cancer to bone: a fatal attraction. Nat Rev Cancer 11:411-425
33. Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, Clement-Lacroix P, Clezardin P (2007) Tumor αvβ3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res 67:5821-5830